Opal Wealth Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$254K Sell
335
-5
-1% -$3.78K 0.05% 172
2026
Q2
$212K Sell
340
-14
-4% -$9.5K 0.05% 206
2026
Q1
$274K Buy
354
+11
+3% +$8.42K 0.06% 160
2025
Q4
$265K Buy
+343
New +$233K 0.07% 171
2025
Q3
– Sell
-342
Closed -$180K – 472
2025
Q2
$180K Buy
342
+98
+40% +$54.7K 0.05% 209
2025
Q1
$155K Buy
+244
New +$168K 0.05% 209
2024
Q4
– Sell
-255
Closed -$268K – 203
2024
Q3
$268K Sell
255
-56
-18% -$62.3K 0.08% 140
2024
Q2
$327K Buy
+311
New +$301K 0.11% 116

Other funds holding REGN

Opal Wealth Advisors's REGN Position: Q3 2026 in Review

Opal Wealth Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 1.5% in Q3 2026, selling an estimated $3.78K and leaving 335 shares worth $254K. The position accounts for 0.05% of the portfolio, ranked #172.

Opal Wealth Advisors first reported a position in REGN in Q2 2024 and has held it in 8 quarters since. The position peaked at $327K in Q2 2024. 1,409 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • Opal Wealth Advisors held 335 shares of Regeneron Pharmaceuticals worth $254K as of Q3 2026.
  • Opal Wealth Advisors sold 5 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $3.78K.
  • Regeneron Pharmaceuticals made up 0.05% of Opal Wealth Advisors's portfolio in Q3 2026, its #172 holding.
  • Opal Wealth Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • Opal Wealth Advisors's Regeneron Pharmaceuticals position peaked at $327K in Q2 2024.
  • 1,409 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Opal Wealth Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.